Hematologic Malignancy
Primary Amyloidosis
CI-CAN-00008290Explore in graph →
HematologicNon-malignant32 active trials
- NCIt
- C3819
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008290Explore in graph →
Clinical trials
106 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03283917 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | completed | Phase 1 | 30 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05199337 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis |
| completed |
| Phase 1 / Phase 2 |
| 18 |
| K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY |
| 7 |
| Sep 19, 2024 |
| clinicaltrials |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | completed | Phase 1 / Phase 2 | 28 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01570387 | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Boston Medical CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00807872 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 40 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT01815086 | Radioimmunoimaging of Light Chain (AL) Amyloidosis | completed | Phase 1 | 30 | University of TennesseeOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01409148 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 38 | University of TennesseeOTHER | 1 | Oct 11, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jul 9, 2026source: clinicaltrials